CD73: A potential biomarker for anti-PD-1 therapy

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Beavis, Paul A ^a,b,c   Slaney, Clare Y ^a,b,c   Milenkovski, Nicole ^a,b,c   Henderson, Melissa A ^a,b,c   Loi, Sherene ^a,b,c   Stagg, John ^c,d   Kershaw, Michael H ^a,b,c,e   Darcy, Phillip K ^a,b,c,e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

adenosine; anti PD 1; cancer; CD73; immunotherapy

Indexed keywords

5' NUCLEOTIDASE; BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANZYME B; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 84941774489     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1046675     Document Type: Article

References (10)

1. J.M.Taube, A.P.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
2. P.A.Beavis, N.Milenkovski, M.A.Henderson, L.B.John, B.Allard, S.Loi M.H.Kershaw, J.Stagg, P.K.Darcy. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 2015; in press; PMID:25672397
3. S.Loi, S.Pommey, B.Haibe-Kains, P.A.Beavis, P.K.Darcy, M.J.Smyth, J.Stagg. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 2013; 110 (27):11091-6; PMID:23776241; http://dx.doi.org/10.1073/pnas.1222251110
4. R.Iannone, L.Miele, P.Maiolino, A.Pinto, S.Morello. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res 2014; 4:172-81; PMID:24660106
5. R.D.Leone, Y.-C.Lo, J.D.Powell. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J 2015; 13:265-72; http://dx.doi.org/10.1016/j.csbj.2015.03.008
6. P.A.Beavis, U.Divisekera, C.Paget, M.T.Chow, L.B.John, C.Devaud, K.Dwyer, J.Stagg, M.J.Smyth, P.K.Darcy. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 2013; 110:14711-6; PMID:23964122; http://dx.doi.org/10.1073/pnas.1308209110
7. S.M.Hatfield, J.Kjaergaard, D.Lukashev, T.H.Schreiber, B.Belikoff, R.Abbott, S.Sethumadhavan, P.Philbrook, K.Ko, R.Cannici et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 2015; 7:277ra30; PMID:25739764; http://dx.doi.org/10.1126/scitranslmed.aaa1260
8. C.Cekic, J.Linden. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res 2014; 74:7239-49; PMID:25341542; http://dx.doi.org/10.1158/0008-5472.CAN-13-3581
9. M.A.Curran, W.Montalvo, H.Yagita, J.P.Allison. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107
10. D.Mittal, A.Young, K.Stannard, M.Yong, M.W.Teng, B.Allard, J.Stagg, M.J.Smyth. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res 2014; 74:3652-8; PMID:24986517; http://dx.doi.org/10.1158/0008-5472.CAN-14-0957